A new study from the University of Kentucky Maxwell H. Gluck Equine Research Center is challenging long-held assumptions about carpal bone chips in Thoroughbred yearlings. Researchers found that the presence of such chips may not be the career-ending defect buyers often assume. The findings carry significant financial implications for sellers and consignors who have watched prices plummet when a chip is flagged.
At yearling sales, a veterinarian's report of a bone chip on a radiograph typically triggers concern. Buyers frequently step away, and prices drop accordingly. The industry has long viewed such horses as already compromised, but the study suggests that perception may not align with reality.
The research analyzed buyer assumptions and their economic consequences, though specific data on the prevalence of chips or their long-term impact on racing careers remains limited. The study does not provide exact figures on how much prices typically drop when a chip is detected.
For sellers, these findings could shift negotiation dynamics at future sales. If buyers adjust their risk assessment, the price discounts historically applied to chip-positive yearlings may decrease. Consignors may also change how they present veterinary reports.
The study's authors caution that more research is needed to fully understand the long-term outcomes for affected horses. The findings represent an initial step toward re-evaluating industry norms.